Data on 968 diabetes patients who had percutaneous coronary intervention revealed those who used paclitaxel-eluting stents had higher thrombosis rates at six and 12 months and higher mortality at one year compared with those who were treated with everolimus-eluting stents. The findings appear in Catheterization and Cardiovascular Interventions.
Study: Diabetes patients may do better with everolimus stents
SmartBrief Job Listings for Health Care
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.